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Delineating CSF-1-dependent regulation of myeloid cell diversity in tumors Myeloid cells contribute to increased malignancy and poor prognosis in breast cancer. We demonstrate that anti-CSF-1R therapy depletes a cell population sharing characteristics of tumor-associated macrophages (TAMs) and dendritic cells (DCs). Intravital imaging combined with cellular characterization has refined our understanding of anti-CSF-1R therapy on the tumor microenvironment.
Tumor-infiltrating Myeloid Cells Promote Tumor Progression
Tumors function as complex organs that shape their microenvironment through the interaction with stromal cells, consisting of fibroblasts, adipocytes, blood and lymph vessels, and immune cells. 1 As tumors progress, tumor-derived growth factors lead to evolving phenotypes of tumor-associated myeloid cells that can contribute to tumor initiation and progression by a wide range of mechanisms. 2 In human breast cancer and most other solid tumors, high numbers of tumorassociated myeloid cells, along with high expression of the myeloid colony-stimulating factor ¡1 (CSF-1), 3 correspond to poor prognosis.
CSF-1 Dependent and Independent Tumor-associated Myeloid Cells
Due to the plasticity of macrophages, the complex spectrum of macrophage activation and the lack of cell surface markers that are distinct to subsets of macrophages, 4,5 a clear understanding of macrophage diversity and function within the tumor and during tumor progression cannot be delineated by immunohistochemistry and flow cytometry alone. In addition to these methods, we therefore utilized intravital microscopy, in combination with targeted therapy against CSF-1R, to provide unique insight into the cellular composition and real-time dynamics of the stromal microenvironment. 6 Our goal was to characterize the evolving phenotype of TAMs and their dynamic interplay with the microenvironment during tumor progression. We utilized the MMTV-PyMT/c-fms-EGFP mouse model of breast cancer, which mimics the stages of tumor progression observed in humans, and the IgG 1 M279 blocking monoclonal antibody to the CSF-1R.
Using intravital imaging, we identified a c-fms-EGFP population of sessile myeloid cells that localized closely to the epithelium of tumor nodules and included subpopulations of cells with high endocytic and MMP proteolytic activity. Furthermore, we found these cells expressed macrophage cell surface markers F4/80 and CD115 (CSF-1R), along with classical DC markers CD11c and MHCII using flow cytometry. Accordingly, these cells were profoundly depleted with the anti-CSF-1R antibody M279. In addition, we observed CSF-1 independent myeloid cell populations in the stroma, which were identified as CD11c 
F480
¡ MHCII hi population is GM-CSF dependent 7 and the Gr1 hi population, which consists predominantly of T cell-suppressive Ly6G C Ly6C int neutrophils, is G-CSF dependent, 8 revealing distinct regulation of these myeloid cell populations in the PyMT model of breast cancer (Fig. 1) .
CSF-1-dependent Regulation of Lung Metastasis During Early Tumor Progression
To determine whether depletion of CSF-1-dependent CD11c 
M1 and M2 Characterization Should Be Avoided
While CSF-1 stimulation as a single agent polarizes macrophages away from an antigen presentation phenotype and induces a different gene expression profile than GM-CSF, CSF-1 dependent macrophages should not be classified as M2 polarized, since their heterogeneity is likely regulated by the microenvironment. 4 Furthermore, while TAMs have been termed M2 or alternatively activated macrophages (AAMs), IL-4 ¡/¡ PyMT mice had normal proportions of TAMs (characterized as CD11b lo MHCII hi VCAM C cells that highly expressed itgax, the gene that encodes CD11c) and TAM differentiation was intact in the absence of lymphocytes, suggesting TAMs are not the same as classical AAMs. 9 Thus, it has been suggested that macrophage heterogeneity should not be simplified on a linear scale between M1 and M2, but should be described in terms of the diversity of points on a color wheel. 4 Future Therapy With CSF-1
Blockade in Cancer CSF-1 blockade depletes macrophage populations in various tumor models, but the effects as a single agent therapy on primary tumor growth is variable. 3 This variability may result from the heterogeneity and relative proportions of macrophage subpopulations in different tumor types and their role (s) in disease progression. Of interest, CSF-1 blockade in combination with radiation, chemotherapy, and immunotherapy has shown synergistic effects. 3 However, one study reported a neutrophil-dependent enhanced metastasis with CSF-1 blockade. 10 A better understanding of the complex interplay between tumor-associated myeloid cells and disease progression in different tumor types is warranted and should provide predictive and prognostic value.
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This study was supported by a grant from the National Cancer Institute (R01 CA057621). showed high endocytic and matrix metalloproteinase (MMP) proteolytic activity and localized close to the epithelium of tumor nodules. CSF-1-independent CD11b C Ly6G C Ly6C int (neutrophils, CSF-3 dependent) and F4/80 neg CD11c C MHCII hi (classical DCs, CSF-2 dependent) localized in the stroma.
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